Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis |
| |
| Authors: | Alain P. Vicari Alain M. Schoepfer Bertrand Meresse Laurence Goffin Olivier Léger Soheila Josserand |
| |
| Affiliation: | 1. Calypso Biotech SA, Plan-les-Ouates, Switzerland;2. Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland;3. INSERM U1163, Institut Imagine, Paris, France;4. Olivier Léger, Saint Sixt, France;5. Novimmune, Plan-les-Ouates, Switzerland |
| |
| Abstract: | Interleukin-15 (IL-15) is a critical regulator of immune responses, especially at mucosal interfaces within the gastro-intestinal tract. Here, we describe the discovery and characterization of a humanized antibody to IL-15. Data from its epitope and mode of action, cell biology and primate pharmacology, as well as translational studies in human samples and in vivo proof-of-concept experiments in mouse models demonstrate the therapeutic potential of this new antibody targeting IL-15 for refractory celiac disease and eosinophilic esophagitis. |
| |
| Keywords: | Antibody celiac disease cis eosinophilic esophagitis humanized interleukin-15 IL-15 trans |
|
|
